Lupron


Also found in: Dictionary.

Lupron

 [loo´pron]
trademark for a preparation of leuprolide, an antineoplastic agent.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

leuprolide acetate (leuprorelin (UK))

Eligard, Lupron, Lupron Depot, Lupron Depot-Ped, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron-3 Month SR Depot, Prostap (UK)

Pharmacologic class: Gonadotropin-releasing hormone (GnRH) analog

Therapeutic class: Antineoplastic

Pregnancy risk category X

Action

Inhibits and desensitizes GnRH receptors, thus inhibiting gonadotropin secretion when given continuously. This inhibition causes initial increase and then profound decrease in luteinizing hormone and follicle-stimulating hormone levels and, ultimately, reduces testosterone and estrogen sex hormones.

Availability

Eligard Depot: 7.5 mg, 22.5 mg, 30 mg, 45 mg

Injection: 1 mg/0.2 ml

Lupron Depot injection: 3.75 mg/ml, 7.5 mg/ml

Lupron Depot-3 month injection: 11.25 mg, 22.5 mg

Lupron Depot-4 month injection: 30 mg

Lupron Depot-Ped injection: 7.5 mg, 11.25 mg, 15 mg

Indications and dosages

Advanced prostate cancer

Adults: 1 mg subcutaneously daily (1 mg/0.2-ml formulation). For Lupron Depot formulation, 7.5 mg I.M. monthly, 22.5 mg I.M. q 3 months, or 30 mg I.M. q 4 months. For Eligard formulation, 7.5 mg subcutaneously monthly, 22.5 mg subcutaneously q 3 months, 30 mg subcutaneously q 4 months, or 45 mg subcutaneously q 6 months.

Endometriosis

Adults: 3.75 mg I.M. (depot injection) as a single injection once monthly, or 11.25 mg I.M. q 3 months. Duration is up to 6 months.

Adjunct to iron therapy in anemia caused by uterine leiomyomas

Adults: 3.75 mg I.M. monthly or 11.25 mg I.M. q 3 months as a single dose. Recommended duration is 6 months or less.

Central precocious puberty

Children: 50 mcg/kg/day subcutaneously as a single injection, increased in increments of 10 mcg/kg/day as needed

Children weighing more than 37.5 kg (82.5 lb): Initially, 15 mg of Depot-Ped I.M. q 4 weeks, increased in increments of 3.75 mg q 4 weeks as needed

Children weighing 25 to 37.5 kg (55 to 82.5 lb): Initially, 11.25 mg of Depot-Ped I.M. q 4 weeks, increased in increments of 3.75 mg q 4 weeks as needed

Children weighing less than 25 kg (55 lb): Initially, 7.5 mg of Depot-Ped I.M. q 4 weeks, increased in increments of 3.75 mg q 4 weeks as needed

Contraindications

• Hypersensitivity to drug, its components, GnRH, or other GnRH analogs

• Undiagnosed abnormal vaginal bleeding

• Pregnancy or breastfeeding

Precautions

Use cautiously in:

• renal, hepatic, or cardiac impairment.

Administration

• Give Eligard within 30 minutes of mixing. After this time, discard.

• Administer Lupron injection immediately after mixing. Otherwise, discard.

• Administer Lupron Depot-Ped only under prescriber's supervision.

Adverse reactions

CNS: anxiety, depression, dizziness, drowsiness, asthenia, fatigue, headache, vertigo, syncope, mood changes

CV: palpitations, angina, arrhythmias, myocardial infarction

EENT: blurred vision

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia

GU: urinary frequency, hematuria, decreased testes size, erectile dysfunction, decreased libido, gynecomastia

Hematologic: anemia, thrombocytopenia

Respiratory: dyspnea, pleural rub, worsening of pulmonary fibrosis, pulmonary embolism

Skin: alopecia, pruritus, rash, diaphoresis

Other: sour taste, edema, hot flashes, anaphylaxis

Interactions

Drug-diagnostic tests. Blood urea nitrogen, creatinine: increased levels

Pituitary-gonadal system tests: misleading results during and for up to 3 months after therapy

Patient monitoring

• Observe injection site for local reactions.

Monitor cardiovascular and respiratory status carefully to detect serious adverse reactions.

• Evaluate neurologic status. Institute safety measures as needed to prevent injury.

• Periodically monitor serum testosterone and prostate-specific antigen levels.

Patient teaching

• Inform patient that localized reaction may occur at injection site. Tell him to contact prescriber if symptoms don't resolve.

• Advise patient and family to watch for and report signs or symptoms of depression.

• Tell patient drug may cause libido changes or erectile dysfunction. Encourage him to discuss these problems with prescriber.

• Teach patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.

Instruct female of childbearing age to use reliable contraception during therapy. Tell her to stop drug immediately and contact prescriber if she suspects pregnancy.

Tell female patient not to breastfeed.

• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved

Lupron

(lo͞o′prŏn′)
A trademark for the drug leuprolide acetate.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.

Lupron®

Oncology A depot leuprolide, a GnRH–gonadotropin releasing hormone, for palliating advanced prostate CA. See Prostate CA.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
But stopping Lupron can cause psychological stress for those transitioning from male to female, as facial hair can start to grow and the voice may deepen after only a few months.
Leuprolide acetate (750 [micro]g/kg IM; Lupron) was administered twice at a 2-week interval in the postoperative period to suppress ovarian activity and reduce the risk of ectopic ovulation after salpingohysterectomy.
In conjunction with the trial, the study will determine the safety and evaluate the PK/PD metrics of two different oral doses of the company's Ovarest in comparison to the leuprolide formulation approved for the treatment of endometriosis, Lupron Depot 3.75 mg, a monthly intramuscular injection.
Treatment protocols include: a) luteal phase gonadotropin-releasing hormone (GnRH) agonist (low-, regular-, or high-dose leuprolide acetate; Lupron); b) follicular phase GnRH agonist/flare stimulation; or c) GnRH antagonist.
Endocrinologists recommend the use of puberty blocking hormones, such as Lupron (leuproride), in order to protect voice quality and other gender-specific secondary sex characteristics until patients can become old enough to make an informed decision.
Ovarian suppression was induced for 6 months with gonadotropin-releasing hormone (GnRH)-agonist (Lupron); after 3 months all were randomized to 4 weeks of estradiol (E2) or progesterone (P4).
Here's an example: One drug frequently used to suppress ovarian function is leuprolide acetate (Lupron).
After that, she typically injects Lupron, a hormone approved to treat advanced prostate cancer.
At this time she was receiving combination epigenetic therapies with hormonal blockade, consisting of GnRH blockade (Lupron) as well as Tamoxifen at 5 mg every other day (1/8 normal dose of 20 mg per day).